PE-22-28

Derived from the naturally occurring antidepressant peptide spadin, PE-22-28 represents an attempt to create a more stable synthetic version for neuropsychiatric research. Scientists initially developed spadin from spider venom components, and this analog maintains the core structural features believed responsible for mood regulation. Neuroscience laboratories studying depression alternatives have gravitated toward PE-22-28 due to its potential for rapid-acting effects.

PE-22-28 targets TREK-1 potassium channels in brain neurons, blocking these channels in ways that traditional antidepressants don't address. When these potassium channels are inhibited, neurons become more excitable and may release mood-regulating neurotransmitters more readily. This represents a fundamentally different approach from serotonin-based antidepressants, potentially explaining why effects might appear faster than conventional treatments.